The 12-month PRECISE-AD topline data in Q1 2027 is the next major catalyst. The interim safety and biomarker signals are favorable but blinded; unblinded efficacy data will determine the stock's direction.
Drug in focus
PMN drug pipeline →PMN310
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 1b
- Time to market
- Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
- Next catalyst
- None dated
What to watchThe Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $3.48entry
- T+1 · 4d ago −5.46%α −5.10% · $3.29
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ProMIS Neurosciences filed an 8-K with an updated corporate presentation summarizing its PRECISE-AD Phase 1b interim data for PMN310 in early Alzheimer's disease. The presentation highlights zero ARIA-E, 4.4% total ARIA (all mild ARIA-H), and declining biomarker signals (plasma pTau217 -15%, CSF MTBR-tau243 -13.3%) at the 6-month blinded interim, with 12-month topline data expected in Q1 2027.
Key Facts
- PRECISE-AD Phase 1b 6-month blinded interim: 0.0% ARIA-E, 4.4% total ARIA (all mild ARIA-H), no treatment-related SAEs or discontinuations.
- Plasma pTau217 declined 15% from baseline at Day 169; 68.5% of patients declined.
- CSF MTBR-tau243 declined 13.3% from baseline at Day 169; 62.5% of patients declined.
- 144 patients enrolled across 22 sites; 136 safety-evaluable; 61% APOE4 carriers, 11% homozygotes.
- 12-month topline data expected in Q1 2027; cash runway through 2027.
- PMN310 has FDA Fast Track designation.
Financial Impact
No financial data in filing; market cap $36M. Filing is an investor presentation update with no revenue or financial results.
Risk Factors
- Blinded interim data may not predict unblinded 12-month results; Phase 1b is not powered for statistical significance on clinical endpoints.
- Early-stage clinical data may not replicate in larger registrational trials.
- Cash runway through 2027 depends on no unforeseen capital needs.
- Cross-trial comparisons with approved anti-amyloid therapies are illustrative, not head-to-head.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-125896 |
| Document: pmn-20261111x8k.htm | 0001104659-26-125896 |
| Document: 0001104659-26-125896-index-headers.html | 0001104659-26-125896 |
| Document: 0001104659-26-125896-index.html | 0001104659-26-125896 |
| Document: 0001104659-26-125896.txt | 0001104659-26-125896 |
Track record
16 reports on PMN
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +43.16% at T+60 after the Mar 18, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 17, 2026today Press Release Neutral 3/10 Entry $3.28 Now $3.31 +0.91% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.25 Now $3.31 +1.85% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $3.29 to $3.31 Now $3.31 +0.61% ▲ +0.61% +2.52% vs SPY
- Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
- Nov 12, 20264d ago 8-K Neutral 5/10 Viewing Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 4/10 Entry $4.16 to $4.05 Now $3.31 −20.43% ▼ −2.64% −5.01% vs SPY
- Nov 5, 202611d ago Press Release Neutral 2/10 Entry $3.65 to $4.16 Now $3.31 −9.32% ▲ +13.97% +13.66% vs SPY
- Oct 6, 20265w ago 3 Neutral 2/10 Entry $9.12 to $9.15 Now $3.31 −63.71% ▲ +0.33% +0.75% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $9.21 to $9.12 Now $3.31 −64.06% ▼ −0.98% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 3/10 Entry $13.35 to $13.98 Now $3.31 −75.21% ▲ +4.68% +4.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers